Anzupgo is the first topical pan-Janus kinase (JAK) inhibitor to be approved in Switzerland specifically for moderate to ...

LEO’s topical cream formulation of the pan-JAK inhibitor proved to be more effective than oral therapy alitretinoin in the DELTA FORCE study, which involved adults with moderate to severe CHE.

Danish dermatology specialist LEO Pharma today announced that Swissmedic, Switzerland’s national regulatory agency for ...

The European Commission (EC) has granted marketing authorisation to LEO Pharma’s Anzupgo (delgocitinib) cream for treating ...

Delgocitinib cream data will include the final results ... dermatitis and chronic hand eczema," says Shannon Schneider, LEO Pharma VP Medical Affairs, North America. "The depth of LEO Pharma ...

Denmark--(BUSINESS WIRE)--NOT FOR UK USE – NOT INTENDED FOR UK MEDIA LEO Pharma A/S, a global leader in medical dermatology, today announces the launch of Anzupgo ® (delgocitinib) cream in ...

LEO Pharma A/S, a global leader in medical dermatology, announces the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema ...

LEO Pharma A/S, a global leader in medical dermatology, today announces the launch of Anzupgo® (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe Chronic ...